Shionogi

December 02, 2019

Go or no go? Vascepa’s finale and Allergan's pain relief

Amarin’s Vascepa and Allergan’s migraine project ubrogepant are the high-profile pending FDA approval decisions as the sector heads into the last month of the year.

Go or no go? Vascepa’s finale and Allergan's pain relief

Go or no go? Agile and Lipocine hope to make it third time lucky

Roche tries again with a new pill for flu

Upcoming events – Dova’s US verdict and Glaxo’s valuable HIV doublet data

Seattle disappoints Puma bulls with Cascadian takeout

Therapy focus – No safe haven for bio in spinocerebellar ataxia

Axovant scraps Alzheimer’s bid – now back to the amyloid hypothesis

Flurry of FDA activity raises hopes for 2017 approval tally

Upcoming events – Achaogen’s antibiotic and Nektar tries out its opioid again

Rigel gets another chance with fostamatinib

Viiv-Bristol HIV deal ramps up asset swap stakes

Latest Reports

Vantage 2020 Preview

Vantage Pharma, Biotech & Medtech Half-Year Review 2019

Editor's Picks

What makes a great year for takeovers?

Surprise! There’s a tumour in which Keytruda doesn’t work

Gene therapy clinical holds take centre stage

Plenty of choice remains for buyers of gene therapy

Uncovering biopharma’s hidden treasures